iBio (IBIO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
IBIO ends flat (+0.0%) to $0.78, 3 down days in a row. Closed at $0.78, +0.00% vs the prior close of $0.78. Day range $0.75–$0.82, opened at $0.75.
IBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IBIO ends flat (+0.0%) to $0.78, 3 down days in a row
- Closed at $0.78, +0.00% vs the prior close of $0.78. Day range $0.75–$0.82, opened at $0.75.
- Volume was 348.50K shares, 0.5x its 50-day average of 750.52K — lighter than usual.
- Price is -37.2% vs its 50-day average ($1.24) and -56.0% vs its 200-day average ($1.77).
- 52-week range $0.73–$3.82; today's close sits at 2% of that range, 79.6% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — IBIO ends flat (+0.0%) to $0.78 on 2.0x normal volume
- Closed at $0.78, +0.00% vs the prior close of $0.78. Day range $0.73–$0.81, opened at $0.78.
- Volume was 1.43M shares, 2.0x its 50-day average of 731.57K — unusually heavy trading.
- Price is -37.8% vs its 50-day average ($1.25) and -56.1% vs its 200-day average ($1.78).
- 52-week range $0.73–$3.82; today's close sits at 2% of that range, 79.6% below the 52-week high.
Oct 13, 2026 — IBIO slides 13.3% to $0.78, a 52-week low on 1.9x normal volume
- Closed at $0.78, -13.33% vs the prior close of $0.90. Day range $0.77–$0.90, opened at $0.90.
- Volume was 1.34M shares, 1.9x its 50-day average of 714.10K — unusually heavy trading.
- Price is -38.5% vs its 50-day average ($1.27) and -56.3% vs its 200-day average ($1.78).
- 52-week range $0.77–$3.82; today's close sits at 0% of that range, 79.6% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — IBIO jumps 3.4% to $0.90
- Closed at $0.90, +3.45% vs the prior close of $0.87. Day range $0.88–$0.95, opened at $0.89.
- Volume was 452.10K shares, 0.6x its 50-day average of 719.63K.
- Price is -29.7% vs its 50-day average ($1.28) and -49.7% vs its 200-day average ($1.79).
- 52-week range $0.78–$3.82; today's close sits at 4% of that range, 76.4% below the 52-week high.
Oct 9, 2026 — IBIO slides 5.4% to $0.87, a 6-month low on 2.4x normal volume
- Closed at $0.87, -5.43% vs the prior close of $0.92. Day range $0.85–$0.97, opened at $0.92.
- Volume was 1.64M shares, 2.4x its 50-day average of 695.24K — unusually heavy trading.
- Price is -32.6% vs its 50-day average ($1.29) and -51.5% vs its 200-day average ($1.79).
- 52-week range $0.78–$3.82; today's close sits at 3% of that range, 77.2% below the 52-week high.
- That makes 5 straight losses.
Oct 8, 2026 — IBIO slides 8.9% to $0.92, a 6-month low, 4 down days in a row
- Closed at $0.92, -8.91% vs the prior close of $1.01. Day range $0.90–$1.00, opened at $1.00.
- Volume was 684.80K shares, 1.0x its 50-day average of 697.60K.
- Price is -29.3% vs its 50-day average ($1.30) and -48.9% vs its 200-day average ($1.80).
- 52-week range $0.78–$3.82; today's close sits at 5% of that range, 75.9% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — IBIO slides 3.8% to $1.01, a 6-month low on 4.1x normal volume
- Closed at $1.01, -3.81% vs the prior close of $1.05. Day range $0.97–$1.06, opened at $1.05.
- Volume was 2.71M shares, 4.1x its 50-day average of 663.71K — unusually heavy trading.
- Price is -22.9% vs its 50-day average ($1.31) and -44.1% vs its 200-day average ($1.81).
- 52-week range $0.78–$3.82; today's close sits at 8% of that range, 73.6% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — IBIO slides 6.3% to $1.05, a 6-month low on 1.8x normal volume
- Closed at $1.05, -6.25% vs the prior close of $1.12. Day range $1.02–$1.15, opened at $1.12.
- Volume was 1.21M shares, 1.8x its 50-day average of 660.46K — unusually heavy trading.
- Price is -20.3% vs its 50-day average ($1.32) and -42.0% vs its 200-day average ($1.81).
- 52-week range $0.78–$3.82; today's close sits at 9% of that range, 72.5% below the 52-week high.
Oct 5, 2026 — IBIO dips 0.9% to $1.12
- Closed at $1.12, -0.88% vs the prior close of $1.13. Day range $1.08–$1.18, opened at $1.14.
- Volume was 1.13M shares, 1.7x its 50-day average of 662.20K.
- Price is -15.5% vs its 50-day average ($1.33) and -38.3% vs its 200-day average ($1.81).
- 52-week range $0.78–$3.82; today's close sits at 11% of that range, 70.7% below the 52-week high.
Oct 2, 2026 — IBIO rises 1.8% to $1.13
- Closed at $1.13, +1.80% vs the prior close of $1.11. Day range $1.07–$1.15, opened at $1.12.
- Volume was 531.20K shares, 0.8x its 50-day average of 660.87K.
- Price is -15.1% vs its 50-day average ($1.33) and -37.9% vs its 200-day average ($1.82).
- 52-week range $0.78–$3.82; today's close sits at 12% of that range, 70.4% below the 52-week high.
IBIO latest news & SEC filings
Every SEC filing by or about IBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Sep 4, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 28, 2026 · Form 10-K — Annual report
Annual report (audited full-year financial statements and business review)
Fiscal year ended Jun 30, 2026:
- Revenue: $100.00K (prior year $400.00K) (-75.0% vs Jun 30, 2025)
- Net income: -$33.04M (prior year -$18.38M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.32 (prior year -$1.75) (loss narrowed vs Jun 30, 2025)
Aug 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 20, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade IBIO
- Last results release: Aug 28, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Feb 10, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 27, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.64% (largest 13.3%). That is a volatile stock.
- Liquidity: about 842.47K shares (≈$657.12K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.78 vs a range of $0.73–$3.82 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Marc Banjak bought 12,500 shares on Mar 26, 2026.
- Latest filings: 8-K Oct 13, 2026; 8-K Sep 14, 2026; 10-K Aug 28, 2026.
- Share count: 64.31M shares outstanding (Aug 27, 2026), +227.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
IBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.75 | 0.82 | 0.75 | 0.78 | 348.50K |
| Oct 14, 2026 | 0.78 | 0.81 | 0.73 | 0.78 | 1.43M |
| Oct 13, 2026 | 0.90 | 0.90 | 0.77 | 0.78 | 1.34M |
| Oct 12, 2026 | 0.89 | 0.95 | 0.88 | 0.90 | 452.10K |
| Oct 9, 2026 | 0.92 | 0.97 | 0.85 | 0.87 | 1.64M |
| Oct 8, 2026 | 1.00 | 1.00 | 0.90 | 0.92 | 684.80K |
| Oct 7, 2026 | 1.05 | 1.06 | 0.97 | 1.01 | 2.71M |
| Oct 6, 2026 | 1.12 | 1.15 | 1.02 | 1.05 | 1.21M |
| Oct 5, 2026 | 1.14 | 1.18 | 1.08 | 1.12 | 1.13M |
| Oct 2, 2026 | 1.12 | 1.15 | 1.07 | 1.13 | 531.20K |
| Oct 1, 2026 | 1.18 | 1.21 | 1.10 | 1.11 | 337.90K |
| Sep 30, 2026 | 1.19 | 1.22 | 1.17 | 1.18 | 227.90K |
| Sep 29, 2026 | 1.20 | 1.20 | 1.16 | 1.17 | 234.30K |
| Sep 28, 2026 | 1.19 | 1.19 | 1.15 | 1.17 | 295.60K |
| Sep 25, 2026 | 1.23 | 1.24 | 1.15 | 1.19 | 617.60K |
| Sep 24, 2026 | 1.25 | 1.25 | 1.19 | 1.20 | 376.30K |
| Sep 23, 2026 | 1.32 | 1.35 | 1.24 | 1.25 | 363.70K |
| Sep 22, 2026 | 1.28 | 1.37 | 1.24 | 1.33 | 2.09M |
| Sep 21, 2026 | 1.29 | 1.31 | 1.26 | 1.26 | 385.50K |
| Sep 18, 2026 | 1.26 | 1.30 | 1.24 | 1.28 | 440.60K |
About iBio
iBio (IBIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends June 30. SEC CIK 1420720.
IBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| David Arkowitz | Director | Nov 24, 2025 |
| Martin Brenner | See Remarks | Mar 23, 2026 |
| William D Clark | Director | Nov 24, 2025 |
| Alexandra Kropotova | Director | Nov 24, 2025 |
| Antonio Bernardino Guimaraes Parada | Director | Nov 24, 2025 |
| Evert B. Schimmelpennink | Director | Nov 24, 2025 |
| Gary Sender | Director | Nov 24, 2025 |
| Elizabeth Stoner | Director | May 19, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Marc Banjak | Chief Legal Officer | Mar 27, 2026 |
| Martin Brenner | See Remarks | Mar 23, 2026 |
| Molly Carr | Chief Medical Officer | Aug 4, 2026 |
| Felipe Duran | Chief Financial Officer | Mar 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 26, 2026 | Marc Banjak | Buy | 12,500 | $1.64 |
| Mar 26, 2026 | Marc Banjak | Buy | 1,434 | $1.76 |
| Mar 19, 2026 | Felipe Duran | Buy | 24,835 | $2.02 |
| Mar 19, 2026 | Martin Brenner | Buy | 12,336 | $2.02 |
IBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Jun 30, 2026 | $100.00K | $-33.04M | -0.32 | $-23.22M |
| Jun 30, 2025 | $400.00K | $-18.38M | -1.75 | $-15.30M |
| Jun 30, 2024 | $225.00K | $-24.91M | -6.50 | $-18.55M |
| Jun 30, 2023 | $0 | $-65.01M | -106.19 | $-30.44M |
| Jun 30, 2022 | — | $-50.30M | -5.78 | $-37.48M |
Latest balance sheet: total assets $99.11M, total liabilities $13.40M, cash $56.40M (as of Jun 30, 2026).
IBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 28, 2026 | 8-K Item 2.02 (results) | $1.36 |
| May 12, 2026 | 8-K Item 2.02 (results) | $1.61 |
| Feb 10, 2026 | 8-K Item 2.02 (results) | $2.27 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.25 |
| Sep 5, 2025 | 8-K Item 2.02 (results) | $0.84 |
| Aug 18, 2025 | 8-K Item 2.02 (results) | $0.74 |
| May 2, 2025 | 8-K Item 2.02 (results) | $1.01 |
| Feb 10, 2025 | 8-K Item 2.02 (results) | $3.42 |
| Nov 25, 2024 | 8-K Item 2.02 (results) | $2.56 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $2.55 |
| Sep 20, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)AMD (AMD)Apple (AAPL)Tesla (TSLA)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.